Burnout: evaluation of the efficacy and tolerability of TARGET 1® for professional fatigue synd
A 12-week, double-blind, randomized, placebo-controlled trial was conducted in workers engaged in professional contact with patients, students or clients. All were affected by burnout syndrome based on a score of ≥4 on the Burnout Measure Scale (BMS-10). The primary outcome measure was the change in the BMS-10 score; secondary outcome measures included the change in the Maslach's Burnout Inventory scale-Human Service Survey (MBI-HSS) score and the Beck Depression Inventory. Five scores were evaluated.
Eighty-seven participants were enrolled in the study: 44 received the active formulation (verum group), 43 received placebo. After 12 weeks' supplementation, the placebo group showed significant improvements in scores for BMS-10, MBI-HSS fatigue and the Beck Depression Inventory, but MBI-HSS depersonalization and task management were not improved; the verum group showed significant improvements in all five scores. The verum group consistently showed significantly greater improvements in scores than the placebo group.
TARGET 1® significantly improved the symptoms of burnout after 12 weeks' use.
Burnout: evaluation of the efficacy and tolerability of TARGET 1® for professional fatigue syndrome (burnout)
J Int Med Res.